Clinial Significance of Angiogenic Factors VEGF,bFGF,HGF Serum Concentrations in Multiple Myeloma

陈盛亭,李扬秋,张学利,陈少华,钟隽,张涛

DOI: https://doi.org/10.3969/j.issn.1004-583x.2004.08.006

2004-01-01

Abstract:Objective To study the relationship of angiogenic cytokines vascular endothelial growth factor(VEGF)、basic fibroblast growth factor(bFGF)、hepatocyte growth factor(HGF) with multiple myeloma (MM), and to explore their clinical significances. Methods The serum levels of VEGF,bFGF,HGF and IL-6 were detected by enzyme-linked immunosobant assay technique in 32 patients with MM and in 20 controls (healthy volunteers). The associations between the cytokines serum levels with MM stages (Ⅰ-Ⅲ) and with MM therapeutic effect were observed. Results Pretreatment MM had significantly higher VEGF,bFGF,HGF serum levels than controls. No obvious difference of IL-6 serum level was found between MM patients and healthy volunteers. Pretreatment serum levels of VEGF were significantly lower in stage Ⅰ,Ⅱ than in stage Ⅲ MM, and between stage Ⅰ and stage Ⅱ there was no significant difference. Pretreatment serum levels of bFGF,HGF were significantly elevated in stage Ⅰ,stage Ⅱ and stage Ⅲ, respectively. No significant differences of IL-6 serum level were found between stage Ⅰ,stage Ⅱ and stage Ⅲ MM. In the patients responding to chemotherapy a significant decrease in VEGF,bFGF and HGF serum levels occurred, while in the patients who did not achieve a remission, there was no significant decrease in them. Conclusion The serum levels of angiogenic factors VEGF,bFGF,HGF are correlated with the severity of MM and its therapeutic effect, they could be used for a parameter for determining the severity of MM and its respondence to therapy.